SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review

Sodium‐glucose co-transporter 2 (SGLT2) inhibitors have recently emerged as an effective means to protect kidney function in people with type 2 diabetes and chronic kidney disease (CKD). In this review, we explore the role of SGLT2 inhibition in these individuals. SGLT2 inhibitors specifically act t...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Merlin C, Neuen, Brendon L, Twigg, Stephen M, Cooper, Mark E, Badve, Sunil V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448577/
https://www.ncbi.nlm.nih.gov/pubmed/37159343
http://dx.doi.org/10.1530/EC-23-0005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10448577/
https://www.ncbi.nlm.nih.gov/pubmed/37159343
http://dx.doi.org/10.1530/EC-23-0005

Ejemplares similares